Alexandre Barbieri Mestriner1,2, Jakob Ackermann3,4, Gergo Merkely2,5, Pedro Henrique Schmidt Alves Ferreira Galvão1, Luiz Felipe Morlin Ambra1, Andreas H Gomoll6. 1. Universidade Federal de São Paulo-Escola Paulista de Medicina, São Paulo, Brazil. 2. Cartilage Repair Center, Brigham and Women's Hospital, Harvard Medical Center, Boston, MA, USA. 3. Sports Medicine Center, Massachusetts General Hospital, Boston, MA, USA. 4. Balgrist University Hospital, Zurich, Switzerland. 5. Department of Traumatology, Semmelweis University, Budapest, Hungary. 6. Hospital for Special Surgery, New York, NY, USA.
Abstract
OBJECTIVE: To determine the relationship between cartilage lesion etiology and clinical outcomes after second-generation autologous chondrocyte implantation (ACI) in the patellofemoral joint (PFJ) with a minimum of 2 years' follow-up. METHODS: A retrospective review of all patients that underwent ACI in the PFJ by a single surgeon was performed. Seventy-two patients with a mean follow-up of 4.2 ± 2.0 years were enrolled in this study and were stratified into 3 groups based on the etiology of PFJ cartilage lesions: patellar dislocation (group 1; n = 23); nontraumatic lesions, including chondromalacia, osteochondritis dissecans, and degenerative defects (group 2; n = 28); and other posttraumatic lesions besides patellar dislocations (group 3; n = 21). Patient's mean age was 29.6 ± 8.7 years. Patients in group 1 were significantly younger (25.4 ± 7.9 years) than group 2 (31.7 ± 9.6 years; P = 0.025) and group 3 (31.5 ± 6.6 years; P = 0.05). Body mass index averaged 26.2 ± 4.3 kg/m2, with a significant difference between group 1 (24.4 ± 3.2 kg/m2) and group 3 (28.7 ± 4.5 kg/m2; P = 0.005). A clinical comparison was established between groups based on patient-reported outcome measures (PROMs) and failure rates. RESULTS: Neither pre- nor postoperative PROMs differed between groups (P > 0.05). No difference was seen in survivorship between groups (95.7% vs. 82.2% vs. 90.5%, P > 0.05). CONCLUSION: Cartilage lesion etiology did not influence clinical outcome in this retrospective study after second generation ACI in the PFJ. LEVEL OF EVIDENCE: Level III, retrospective comparative study.
OBJECTIVE: To determine the relationship between cartilage lesion etiology and clinical outcomes after second-generation autologous chondrocyte implantation (ACI) in the patellofemoral joint (PFJ) with a minimum of 2 years' follow-up. METHODS: A retrospective review of all patients that underwent ACI in the PFJ by a single surgeon was performed. Seventy-two patients with a mean follow-up of 4.2 ± 2.0 years were enrolled in this study and were stratified into 3 groups based on the etiology of PFJ cartilage lesions: patellar dislocation (group 1; n = 23); nontraumatic lesions, including chondromalacia, osteochondritis dissecans, and degenerative defects (group 2; n = 28); and other posttraumatic lesions besides patellar dislocations (group 3; n = 21). Patient's mean age was 29.6 ± 8.7 years. Patients in group 1 were significantly younger (25.4 ± 7.9 years) than group 2 (31.7 ± 9.6 years; P = 0.025) and group 3 (31.5 ± 6.6 years; P = 0.05). Body mass index averaged 26.2 ± 4.3 kg/m2, with a significant difference between group 1 (24.4 ± 3.2 kg/m2) and group 3 (28.7 ± 4.5 kg/m2; P = 0.005). A clinical comparison was established between groups based on patient-reported outcome measures (PROMs) and failure rates. RESULTS: Neither pre- nor postoperative PROMs differed between groups (P > 0.05). No difference was seen in survivorship between groups (95.7% vs. 82.2% vs. 90.5%, P > 0.05). CONCLUSION: Cartilage lesion etiology did not influence clinical outcome in this retrospective study after second generation ACI in the PFJ. LEVEL OF EVIDENCE: Level III, retrospective comparative study.
Authors: Luiz Felipe Ambra; Betina B Hinckel; Elizabeth A Arendt; Jack Farr; Andreas H Gomoll Journal: Am J Sports Med Date: 2019-07-09 Impact factor: 6.202
Authors: Jakob Ackermann; Gergo Merkely; Alexandre Barbieri Mestriner; Nehal Shah; Andreas H Gomoll Journal: Am J Sports Med Date: 2019-08-21 Impact factor: 6.202
Authors: Cecilia Pascual-Garrido; Mark A Slabaugh; Daniel R L'Heureux; Nicole A Friel; Brian J Cole Journal: Am J Sports Med Date: 2009-10-27 Impact factor: 6.202
Authors: Alberto Gobbi; Elizaveta Kon; Massimo Berruto; Giuseppe Filardo; Marco Delcogliano; Lorenzo Boldrini; Lyndon Bathan; Maurilio Marcacci Journal: Am J Sports Med Date: 2009-06 Impact factor: 6.202